
    
      This is a prospective, multicenter, single-group clinical study of Apatinib Plus Irinotecan
      as second-line treatment in locally advanced or metastatic gastric or gastroesophageal
      junctional adenocarcinoma. Interventions: Irinotecan: 180mg/m2, ivgtt,given on the first day;
      Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the
      same time each day). Repeat the therapeutic schedule every 3 weeks till progressive disease
      or intolerable toxicities. Primary Outcome Measure: PFS. Secondary Outcome Measures: OS, ORR,
      DCR.
    
  